NDLI: Treatment strategies for Parkinson’s disease

Please wait, while we are loading the content...

Treatment strategies for Parkinson’s disease

Content Provider	Springer Nature Link
Author	Yuan, Hong Zhang, Zhen Wen Liang, Li Wu Shen, Quan Wang, Xiang Dang Ren, Su Mei Ma, Hong Jie Jiao, Shu Jun Liu, Ping
Copyright Year	2010
Abstract	Parkinson’s disease (PD) is caused by progressive degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc), resulting in the deficiency of DA in the striatum. Thus, symptoms are developed, such as akinesia, rigidity and tremor. The aetiology of neuronal death in PD still remains unclear. Several possible mechanisms of the degeneration of dopaminergic neurons are still elusive. Various mechanisms of neuronal degeneration in PD have been proposed, including formation of free radicals, oxidative stress, mitochondrial dysfunction, excitotoxicity, calcium cytotoxicity, trophic factor deficiency, inflammatory processes, genetic factors, environmental factors, toxic action of nitric oxide, and apoptosis. All these factors interact with each other, inducing a vicious cycle of toxicity causing neuronal dysfunction, atrophy and finally cell death. Considerable evidence suggests that free radicals and oxidative stress may play key roles in the pathogenesis of PD. However, currently, drug therapy cannot completely cure the disease. DA replacement therapy with levodopa (L-Dopa), although still being a gold standard for symptomatic treatment of PD, only alleviates the clinical symptoms. Furthermore, patients usually experience severe side effects several years after the L-Dopa treatment. Until now, no therapy is available to stop or at least slow down the neurodegeneration in patients. Therefore, efforts are made not only to improve the effect of L-Dopa treatment for PD, but also to investigate new drugs with both antiparkinsonian and neuroprotective effects. Here, the advantages and limitations of current and future therapies for PD were dicussed. Current therapies include dopaminergic therapy, DA agonists, MAO-B inhibitor, COMT inhibitors, anticholinergic drugs, surgical procedures such as pallidotomy and more specifically deep brain stimulation of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN), and stem cell transplantation.帕金森氏病(Parkinson’s disease, PD)是由中脑黑质中多巴胺神经元变性, 导致纹状体系统多巴胺(DA)含量下降引起的神经病变。其特征性症状包括震颤、僵硬和运动徐缓等。目前为止, 帕金森氏病神经元死亡的病因仍不清楚。具体的神经变性机制包括自由基生成、氧化应激、线粒体异常、兴奋性中毒、钙中毒、营养因子不足、炎症过程、一氧化氮毒性和细胞调亡。这些因素相互增强形成恶性循环导致神经功能异常、萎缩, 最终导致多巴胺神经元死亡。大量实验提示在PD 病理过程中, 自由基的生成和氧化应激起关键作用。目前, 药物疗法并不能治愈PD。尽맜左旋多巴(L-Dopa)替代疗法一直是控制PD 症状的标准, 但其只能缓解临床症状, 并且L-Dopa 长期治疗会引起多种副作用。目前尚无可行的疗法能遏制或减缓神经元变性。因此, 研究不仅要致力于改善和延长L-Dopa对PD的治疗效果, 还要研发兼具抗PD与神经保护功能的药物。本文综述了当前各种PD疗法的优缺点。这些疗法包括DA 治疗、 DA 激动剂、单胺氧化酶-B 抑制剂、儿茶酚-O-甲基转移酶抑制剂、抗谷氨酸药、胆碱能药物、外科手术(深部大脑苍白球或丘脑术)和干细胞移植术等。同时, 基于PD 病理过程, 对未来的药物神经保护作一展望。
Starting Page	66
Ending Page	76
Page Count	11
File Format	PDF
ISSN	16737067
Journal	Neuroscience Bulletin
Volume Number	26
Issue Number	1
e-ISSN	19958218
Language	Chinese
Publisher	Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
Publisher Date	2010-02-03
Publisher Place	Heidelberg
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Parkinson’s disease treatment strategy pharmacological neuroprotection Pain Medicine Neurology Anatomy Anesthesiology Human Physiology Neurosciences
Content Type	Text
Resource Type	Article
Subject	Neuroscience Physiology Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Progression of motor symptoms in Parkinson’s disease

Exosomes in Parkinson’s Disease

The effects of dietary choline

ATP-sensitive potassium channels: novel potential roles in Parkinson’s disease

Hyposmia: a possible biomarker of Parkinson’s disease

A New Perspective for Parkinson’s Disease: Circadian Rhythm

How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson’s disease?

Progressive changes of orexin system in a rat model of 6-hydroxydopamineinduced Parkinson’s disease

Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes

Treatment strategies for Parkinson’s disease

Similar Documents

Progression of motor symptoms in Parkinson’s disease

Exosomes in Parkinson’s Disease

The effects of dietary choline

ATP-sensitive potassium channels: novel potential roles in Parkinson’s disease

Hyposmia: a possible biomarker of Parkinson’s disease

A New Perspective for Parkinson’s Disease: Circadian Rhythm

How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson’s disease?

Progressive changes of orexin system in a rat model of 6-hydroxydopamineinduced Parkinson’s disease

Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes

Treatment strategies for Parkinson’s disease